JAK2 and placenta cancer: The ovarian and placental cancer cell line selective inhibitors included actinomycin D [32] (IC50 = 0.78 ± 0.222 μM; SI >100), a DNA intercalator and common drug for GTD, and fedratinib [33] (IC50 = 13.1 ± 7.51 μM; SI >100), a JAK2 inhibitor (Supplementary Figure 6 and Table 3).